Phase I FINAL results are due at any time, and the actual start of Phase II testing in Russia should be announced shorty, originally scheduled to start in Q2:14. The results of Phase II is a long way off, probably mid-2015 for top line data. After receiving Russian approval CardioNova can apply for marketing approval in Russia which will allow CardioNova to commence selling AHRO-001.
I don't believe anything has been announced for Phase III testing, and that would not involve CardioNova, but only AtheroNova, and the earliest probably would not be before mid-2016 if there are no additional delays.
A good source for information on AtheroNova is 'Mont Blanc Capital' who makes a market in this security. William Gregozeski CFA is a great source in my opinion, and he is with Mont Blanc.
Keep in mind the date of this referenced information. The overall schedule has slipped a bit since this was written.
News 
Market Data 
Discover 
AI
